Naveen Pemmaraju: MD Anderson Cancer Center (MDACC) is a special place of hope and inspiration
Quoting Naveen Pemmaraju’s post on LinkedIn:
“When On Service: I am an Attending in the Leukemia Inpatient service this month. MD Anderson Cancer Center (MDACC) is a special place of hope and inspiration.
I am super grateful to our amazing MDACC Leukemia inpatient team including PharmDs (Doctors of Pharmacy), Advanced Practice Providers (APPs), Nurses, Patient Service Centers (PSCs) and all team members who dedicate their lives and careers to the care of our patients and families facing rare blood cancers.”
Source: Naveen Pemmaraju/LinkedIn
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML. He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023